



25<sup>th</sup> March 2021

## Direct Healthcare Professional Communication (DHPC)

### **TECENTRIQ® ▼ (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs)**

Dear Healthcare professional,

Roche Products (Ireland) Limited in agreement with European Medicines Agency (EMA) and the Malta Medicines Authority (MMA) would like to inform you of the following:

#### **Summary**

- **Severe cutaneous adverse reactions (SCARs), including cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in patients treated with Tecentriq (atezolizumab).**
- **Patients should be monitored for suspected severe skin reactions and other causes should be excluded. In case a SCAR is suspected, Tecentriq should be withheld and patients should be referred to a specialist in SCARs for diagnosis and treatment.**
- **In case SJS or TEN is confirmed, and for any grade 4 rash/SCAR, treatment with Tecentriq should be permanently discontinued.**
- **Caution is recommended when considering the use of Tecentriq in patients with previous history of a severe or life-threatening SCAR with other immune-stimulatory cancer medicines.**

#### **Background on the safety concern**

SCARs are a heterogeneous group of immunologically mediated drug eruptions. Although rare, these events are potentially fatal, and are mainly constituted by acute generalised exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS).

**Roche Products  
(Ireland) Limited**

3004 Lake Drive,  
Citywest  
Naas Road, Dublin 24  
Ireland, D24 K661  
(Registered Office)

Tel: 353-1-4690700  
Fax: 353-1-4690790  
353-1-4690791

Registered in Ireland  
No. 214337

#### *Directors:*

A. Muir (British), E. Hassan (Egyptian), G. Cahill (Irish), B. Kraehenmann (Swiss), S. Davis (British - Company Secretary)



SCARs were previously known to be potentially associated with the use of atezolizumab, and have been monitored continuously. Based upon the totality of evidence in a recent analysis, SCARs are now considered to be an identified risk for atezolizumab.

A cumulative analysis of the company safety database across the Tecentriq program identified 99 cases, of which 36 cases of SCARs were confirmed by histopathology or specialist diagnosis, in patients who have received Tecentriq. Approximately 23,654 clinical trial patients and 106,316 patients in post-marketing settings have been exposed to the product as of 17 May 2020. The incidence rates of SCAR, regardless of severity, from pooled atezolizumab monotherapy (N=3178) and combination therapy (N=4371) in company-sponsored clinical studies was 0.7% and 0.6% respectively. This included one fatal case of TEN in a 77-year old female patient who received atezolizumab monotherapy.

It is recommended that:

- For suspected SCARs the patients should be referred to a dermatologist for further diagnosis and management
- Tecentriq should be withheld in patients with suspected SJS or TEN
- Tecentriq should be permanently withdrawn for confirmed SJS or TEN, and for any grade 4 rash/SCAR
- Caution should be used when considering the use of atezolizumab in a patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents.

An update to the EU Product Information to include a Warning and Precaution for SCARs, guidelines for discontinuation and further description of the risk will be implemented shortly.

### **Call for reporting**

▼ TECENTRIQ (atezolizumab) is subject to additional monitoring. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.

Healthcare professionals should report any adverse events suspected to be associated with the use of TECENTRIQ (atezolizumab) to: the Drug Surveillance Centre in Roche Products (Ireland) Limited by telephone (01-4690700) or email (Ireland.drug\_surveillance\_centre@roche.com).

Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form available online at <http://www.medicinesauthority.gov.mt/adrportal> and sent to Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Temi Żammit Buildings, Malta Life Sciences Park, San Ġwann SĠN or sent by email to: [postlicensing.medicinesauthority@gov.mt](mailto:postlicensing.medicinesauthority@gov.mt).

**Roche Products  
(Ireland) Limited**

3004 Lake Drive,  
Citywest  
Naas Road, Dublin 24  
Ireland, D24 K661  
(Registered Office)

Tel: 353-1-4690700  
Fax: 353-1-4690790  
353-1-4690791

Registered in Ireland  
No. 214337

*Directors:*



A. Muir (British), E. Hassan (Egyptian), G. Cahill (Irish), B. Kraehenmann (Swiss), S. Davis (British - Company Secretary)



**Company contact point**

Should you have any questions regarding the use of TECENTRIQ® (atezolizumab), please feel free to contact us Medical Information at Roche Products (Ireland) Limited by telephone (01 4690700) or email (Ireland.druginfo@roche.com).

Yours sincerely,

DocuSigned by:  
  
 Signer Name: James Mawby  
Signing Reason: I approve this document  
Signing Time: 08-Mar-2021 | 6:19:15 PM CET  
0AD24A20DA884201ABE5270A3BADA4AD

---

**Dr. James Mawby**  
**Medical Director**

**Roche Products**  
**(Ireland) Limited**

3004 Lake Drive,  
Citywest  
Naas Road, Dublin 24  
Ireland, D24 K661  
(Registered Office)

Tel: 353-1-4690700  
Fax: 353-1-4690790  
353-1-4690791

Registered in Ireland  
No. 214337

*Directors:*

A. Muir (British), E. Hassan (Egyptian), G. Cahill (Irish), B. Kraehenmann (Swiss), S. Davis (British - Company Secretary)